Boston Scientific announced the acquisition in January, but the review timeline dragged on after the Federal Trade Commission ...

Boston Scientific (NYSE: BSX) today announced the completion of its $3.7 billion acquisition of Axonics, Inc. (Nasdaq: AXNX).

Boston Scientific, a Marlborough medical device manufacturer, has officially closed its acquisition of Axonics Inc. after entering into a purchase agreement in January.

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a ...

The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: ...

Boston Scientific produces less invasive medical ... interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare ...

Boston Scientific Corporation reported 19.3% y ... which includes Urology, Endoscopy, and Neuromodulation, saw a growth of around 10% y/y. The Cardiovascular Segment, which includes Cardiology ...

Neuromodulation led the way with a 17% increase. Urology (10.3%) and Endoscopy (7.8%) followed. Outlook: Boston Scientific forecasts net sales growth for 2024 of approximately 16.5% on a reported ...

Boston Scientific is keeping the ball rolling ... growth among medical surgical tools—including endoscopy, urology and neuromodulation—that totaled $1.479 billion. As a result, the company ...